Anaplastic Astrocytoma – Pipeline Review, 2020

Table of Content:

1. Introduction
   1. Report Overview
2. Anaplastic Astrocytoma - Overview
3. Executive Summary
4. Anaplastic Astrocytoma : Pipeline Assessment
   1. By Stage of Development
   2. By Route of Administration
   3. By Drug Class
   4. By Molecule Type
   5. By Therapy Area / Indication
   6. By Drug Target
   7. By Sponsor
5. Anaplastic Astrocytoma: Company & Drug Profiles
   1. Clinical Stage
      1. ADV/HSV-tk – The Methodist Hospital System
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      2. CC-90010 - Celgene
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      3. INCB7839 – Pediatric Brain Tumor Consortium
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      4. Others
   2. Preclinical
      1. Company Overview
      2. Product Description
      3. R&D Status & Development Activities
      4. Mechanism of Action
      5. Molecule Type
      6. Indications
      7. Route of Administration
      8. Funding
6. Anaplastic Astrocytoma: An Overview on Dormant & Discontinued Pipeline Candidates
   1. Overview
   2. Product Description
   3. Reason for Discontinuation
7. Anaplastic Astrocytoma: Additional Key Insights
   1. Epidemiology Overview: Anaplastic Astrocytoma
   2. Current Market Scenario: Anaplastic Astrocytoma Therapeutics
8. Anaplastic Astrocytoma: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.